Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome (CalciWest)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02854046|
Recruitment Status : Unknown
Verified July 2016 by Nantes University Hospital.
Recruitment status was: Not yet recruiting
First Posted : August 3, 2016
Last Update Posted : August 3, 2016
Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year.
Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh.
Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited.
Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.
|Condition or disease||Intervention/treatment|
|Calciphylaxis||Other: Calcific Uremic Arteriolopathy|
|Study Type :||Observational|
|Estimated Enrollment :||225 participants|
|Observational Model:||Case Control|
|Official Title:||Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort|
|Study Start Date :||August 2016|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||November 2017|
Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
Other: Calcific Uremic Arteriolopathy
Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint "onset of the lesions" and REIN regions belonging
- Description of calcific uremic arteriolopathy in a French population by describing the characteristics of the population, diagnostic and treatment practices and patient outcome. [ Time Frame: Up to 16 months ]
- Study factors determining the patient outcome with calciphylaxis [ Time Frame: Up to 16 months ]
- Study case control of risk factors in the subgroup of patients in extra renal replacement therapy [ Time Frame: Up to 16 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02854046
|Contact: David LARMET BURGEOT, MSc||+33 (0)email@example.com|
|Contact: Maryvonne HOURMANT, PHD||+33(0)firstname.lastname@example.org|
|Principal Investigator:||Maryvonne HOURMANT, PHD||Nantes University Hospital|